Navigation Links
New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform
Date:10/5/2007

or blood vessels.

This study, "Enhancement of Tumor Immunogenicity by 2aG4-IL2 Fusion Protein," was conducted by Dr, Xianming Huang, assistant professor of pharmacology in the laboratory of Dr. Philip Thorpe. Study results are being presented by Dr. Thorpe at the International Conference on Vascular Targeted Therapies in Oncology, Mandelieu, France, October 5th, 2007 at 3:10pm local time (9:10am ET).

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection in the U.S. and India with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results of human studies will not correlate to the results achieved in connection with this preclinical breast cancer animal model, and the uncertainty as to whether the results of future clinical studies will support moving this product candidate forward for the treatment
'/>"/>

SOURCE Peregrine Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Wisconsin Assembly passes capital investment bill, revised CAPCO program not presented
2. Simple, Sensitive, and Rapid Detection of FLAG -Tagged Fusion Proteins
3. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
4. Efficient Cleavage of Fusion Proteins to Yield Native Amino Termini
5. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
6. Principles and applications of electrical cell fusion
7. Principles and applications of electrical cell fusion
8. Production of Hybridomas by Electrofusion
9. Monitoring fluorescence resonance energy transfer (FRET) between GFP fusions in lysates of the yeast Saccharomyces cerevisiae using the Varian Cary Eclipse
10. Comparison of Performance between the AlphaQuest - HTS and the Fusion α Multilabel Reader for Detection of cAMP
11. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Madison, WI (PRWEB) January 22, 2015 Dr. ... at the 12th annual Scripps Natural Supplements Pre-Conference seminar on ... Supplements Conference is an annual continuing education conference for health ... 15th and included the topic of probiotics in health. Dr. ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with ... used for drug discovery to commercial manufacturing, announced today ... Next-Generation Sequencing (NGS) data packages. The NGS analysis ... ensuring the integrity of the gene, validation of the ...
(Date:1/22/2015)... BRUNSWICK , Nueva Jersey , 22 de ... Award for Biomedical Research abre hoy su llamada a ... personas cuya investigación científica ha hecho, o tiene el ... la salud humana. Las nominaciones se aceptarán hasta el ...
(Date:1/22/2015)...  Varian Medical Systems (NYSE: VAR ), world leader ... commitment to sustainability with inclusion on a prestigious list of ... healthcare equipment company among the Corporate Knights Global 100 Most ... at Davos, Switzerland . ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2
... N.C., June 10 Campbell Alliance, the leading,management ... today announced that executives from the firm,s Trade ... Business Intelligence,(CBI) 4th Annual Commercial Contracts and Chargeback ... June 19-20, 2008, at,the Hyatt Regency Philadelphia at ...
... (OTC,Bulletin Board: AGGX.OB) a New York-based biotechnology company, ... anti-angiogenic drugs, announced the,appointment of William Garland PhD ... La Roche, Inc., has directed research and,development programs ... such as,Centaur Pharmaceuticals, Atairgin Technologies, Lpath Therapeutics, Inc.,(LPTN.OB) ...
... Therapeutics Inc. is extremely,pleased to announce the initiation ... IAP,("Inhibitor of Apoptosis Protein") inhibitor, HGS1029 (formerly AEG40826),as ... This small,molecule IAP inhibitor was developed by Aegera ... HGSI ) for oncology development in December 2007. ...
Cached Biology Technology:Campbell Alliance Trade and Distribution Practice to Speak at CBI's Commercial Contracts and Chargeback Management Conference 2Campbell Alliance Trade and Distribution Practice to Speak at CBI's Commercial Contracts and Chargeback Management Conference 3AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs 2AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs 3Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment 2
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in the ... One major trend emerging in this market is ... is important to upgrade biometric solutions to the latest ...
(Date:12/10/2014)... been here before: you desperately need to sign into your online ... answer to your secret question. What,s your dog,s birthday? Who was ... , a digital infrastructure security company, launches the app ... with usernames, passwords and PINs – 1U TM . ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... BOULDER--The use of prescribed burns to manage Western ... footprint. A new study finds that such burns, often ... bigger trees, release substantially less carbon dioxide emissions than ... prescribed burns can be an important piece of a ...
... DC, March 16, 2010 A new study ... research institutions states that forest protection offers one ... to combat climate change. The study, "Indigenous Lands, ... in PLoS Biology , a peer-reviewed scientific ...
... UCSF researchers have discovered that a key cellular defect ... can lead to cancer susceptibility. The scientists also found ... in correcting this defect. According to the study ... fight against cancer and could affect treatment of lymphoma ...
Cached Biology News:Prescribed burns may help reduce US carbon footprint 2Prescribed burns may help reduce US carbon footprint 3Study highlights forest protected areas as a critical strategy for slowing climate change 2Blocking cancer in its path: New cellular defect discovered 2Blocking cancer in its path: New cellular defect discovered 3
Request Info...
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
TCP-1 alpha (H-110)...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: